Aarti Pharmalabs Limited

rs,

May 12, 2025 To, Listing/ Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 SCRIP CODE: 543748 Dear Sir/Madam, To, Listing/ Compliance De

20%

220+ Products 500+ Global Clients 58 6 3 Patents Filed Manufacturing Units USFDA Units 15-20% Global Market Share in Xanthine 50+ Export Countries 2,100+ Employees 3 State-of-the-art R&

0.19x

50+ Export Countries 2,100+ Employees 3 State-of-the-art R&D facilities 50 31 US DMF CEP 0.19x Net Debt/Equity A+ Credit rating Aarti Pharmalabs Limited 2 1COMPANY OVERVIEW 2 BUSINESS

INR 130

ited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 130+ bn (FY25) • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p

19%

OFEPRIS (Mexico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 15,112 15,021 17,714 9,410 19% 20% 23% 24% • Strategically located in western India with proximity to ports 9M-FY22 FY23 FY

23%

exico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 15,112 15,021 17,714 9,410 19% 20% 23% 24% • Strategically located in western India with proximity to ports 9M-FY22 FY23 FY24 FY25

24%

) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 15,112 15,021 17,714 9,410 19% 20% 23% 24% • Strategically located in western India with proximity to ports 9M-FY22 FY23 FY24 FY25 HIGHL

48%

ertise in novel chemistries; Largest manufacturer of Xanthine Derivatives in India Domestic, 48% International, 52% Aarti Pharmalabs Limited Note: FY22 numbers are for a period of 9 months as

52%

istries; Largest manufacturer of Xanthine Derivatives in India Domestic, 48% International, 52% Aarti Pharmalabs Limited Note: FY22 numbers are for a period of 9 months as the demerger date was

21 MW

for a period of 9 months as the demerger date was 1st Jul 2021 4 KEY MILESTONES 2024 • Started 21 MW solar power project at Akola, Maharashtra Expansion of semi-commercial production block at Vapi •

5%

t plant scale in FY25 40+ 70+3 Products developed and manufactured on kilo-lab scale in FY25 5% 70+3 R&D Spend (as a percent of API+Int & CDMO sales ) in FY25 110 3 42 Cr 70+3 R&D Proces

52.6%

QUARTERLY REVENUE BREAK-UP Xanthine Derivatives & Allied Products API & Intermediates CDMO/CMO 52.6% 36.1% 11.3% FY24 43.5% 43.6% 12.9% FY25 34.3% 38.8% 26.9% Q4-FY25 CDMO/CMO API & Inter

Valorem Advisors Disclaimer

1

Valorem Advisors Disclaimer

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review. For further details, please feel free to contact our Investor Relations Representatives: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903 9500 Email: a